163 related articles for article (PubMed ID: 16319409)
1. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder.
Chisholm D; van Ommeren M; Ayuso-Mateos JL; Saxena S
Br J Psychiatry; 2005 Dec; 187():559-67. PubMed ID: 16319409
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
Woodward TC; Tafesse E; Quon P; Lazarus A
Pharmacoeconomics; 2010; 28(9):751-64. PubMed ID: 20623994
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.
Soares-Weiser K; Bravo Vergel Y; Beynon S; Dunn G; Barbieri M; Duffy S; Geddes J; Gilbody S; Palmer S; Woolacott N
Health Technol Assess; 2007 Oct; 11(39):iii-iv, ix-206. PubMed ID: 17903393
[TBL] [Abstract][Full Text] [Related]
4. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.
Bridle C; Palmer S; Bagnall AM; Darba J; Duffy S; Sculpher M; Riemsma R
Health Technol Assess; 2004 May; 8(19):iii-iv, 1-187. PubMed ID: 15147609
[TBL] [Abstract][Full Text] [Related]
5. Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder.
Song J; Sjölander A; Joas E; Bergen SE; Runeson B; Larsson H; Landén M; Lichtenstein P
Am J Psychiatry; 2017 Aug; 174(8):795-802. PubMed ID: 28595491
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder.
Woodward TC; Tafesse E; Quon P; Kim J; Lazarus A
J Med Econ; 2009; 12(4):259-68. PubMed ID: 19769548
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial.
Revicki DA; Hirschfeld RM; Ahearn EP; Weisler RH; Palmer C; Keck PE
J Affect Disord; 2005 Jun; 86(2-3):183-93. PubMed ID: 15935238
[TBL] [Abstract][Full Text] [Related]
8. Acute inpatient treatment, hospitalization course and direct costs in bipolar patients with intellectual disability.
Wu CS; Desarkar P; Palucka A; Lunsky Y; Liu SK
Res Dev Disabil; 2013 Nov; 34(11):4062-72. PubMed ID: 24051362
[TBL] [Abstract][Full Text] [Related]
9. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study.
Kessing LV; Hellmund G; Geddes JR; Goodwin GM; Andersen PK
Br J Psychiatry; 2011 Jul; 199(1):57-63. PubMed ID: 21593515
[TBL] [Abstract][Full Text] [Related]
10. Suicide risk in bipolar disorder during treatment with lithium and divalproex.
Goodwin FK; Fireman B; Simon GE; Hunkeler EM; Lee J; Revicki D
JAMA; 2003 Sep; 290(11):1467-73. PubMed ID: 13129986
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.
Macritchie KA; Geddes JR; Scott J; Haslam DR; Goodwin GM
Cochrane Database Syst Rev; 2001; (3):CD003196. PubMed ID: 11687047
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy and risk of suicidal behaviors among patients with bipolar disorder.
Bowden C; Fawcett J
JAMA; 2004 Feb; 291(8):939; author reply 940. PubMed ID: 14982904
[No Abstract] [Full Text] [Related]
13. Lamotrigine combined with divalproex or lithium for bipolar disorder: a case series.
Redmond JR; Jamison KL; Bowden CL
CNS Spectr; 2006 Dec; 11(12):915-8. PubMed ID: 17146405
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy and risk of suicidal behaviors among patients with bipolar disorder.
Yerevanian BI; Koek RJ; Feusner JD
JAMA; 2004 Feb; 291(8):939; author reply 940. PubMed ID: 14982905
[No Abstract] [Full Text] [Related]
15. Lithium and suicide prevention in bipolar disorder.
Benard V; Vaiva G; Masson M; Geoffroy PA
Encephale; 2016 Jun; 42(3):234-41. PubMed ID: 27000268
[TBL] [Abstract][Full Text] [Related]
16. Medical comorbidity, acute medical care use in late-life bipolar disorder: a comparison of lithium, valproate, and other pharmacotherapies.
Rej S; Yu C; Shulman K; Herrmann N; Fischer HD; Fung K; Gruneir A
Gen Hosp Psychiatry; 2015; 37(6):528-32. PubMed ID: 26254672
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting treatment compliance in patients with bipolar I disorder during prophylaxis: a study from Turkey.
Col SE; Caykoylu A; Karakas Ugurlu G; Ugurlu M
Gen Hosp Psychiatry; 2014; 36(2):208-13. PubMed ID: 24359677
[TBL] [Abstract][Full Text] [Related]
18. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions.
Chisholm D; Sanderson K; Ayuso-Mateos JL; Saxena S
Br J Psychiatry; 2004 May; 184():393-403. PubMed ID: 15123502
[TBL] [Abstract][Full Text] [Related]
19. A new BALANCE in bipolar I disorder.
Licht RW
Lancet; 2010 Jan; 375(9712):350-2. PubMed ID: 20092883
[No Abstract] [Full Text] [Related]
20. A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: the LICAVAL study.
Missio G; Moreno DH; Demetrio FN; Soeiro-de-Souza MG; Dos Santos Fernandes F; Barros VB; Moreno RA
Trials; 2019 Oct; 20(1):608. PubMed ID: 31655626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
